Recon: FDA approves Syndax leukemia therapy; Boston Scientific completes $3.7B Axonics acquisition

• RFK Jr vow to purge FDA sets up collision with Big Pharma (Reuters)
• What to know about RFK Jr.’s views on food, vaccines, abortion, and the FDA (STAT)
• Syndax wins U.S. approval for leukemia treatment (STAT)
• Q&A: American Heart Association president on GLP-1s and ‘common ground’ with the next White House (STAT)
• Medicaid fuels US coverage of Novo, Lilly weight-loss drugs (Reuters)
• Lilly sues US agency over blocking of drug-rebate program (Reuters)
• Boston Scientific closes $3.7B Axonics deal after lengthy review (MedTech Dive)
• VBI Vaccines recalls hepatitis B shot as it winds down operations (Fierce Pharma)
• Cleanup for the IL-23 class in ulcerative colitis as new drugs 'rapidly gained significant momentum': report (Fierce Pharma)

• Exclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds new funds (Endpoints)
• Novo Nordisk launches obesity drug Wegovy in China (Reuters)
• Nigeria begins delayed mpox vaccination programme (Reuters)
• Bangladesh deaths from dengue cross 400 as outbreak worsens (Reuters)
• Bavarian Nordic has $340 mln orders for its mpox, smallpox vaccine in 2025 (Reuters)

• Regenxbio says gene therapy strengthened boys with Duchenne muscular dystrophy (STAT)
• Novo Nordisk readies trial results for next-generation weight-loss drug (The Financial Times)
• A rare neurological disease is Sage’s last, best hope after failures in depression (Endpoints)
• Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges (Endpoints)
• As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers (Endpoints)
• Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset (Endpoints)
• Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edema (Endpoints)
• Atlas Venture targets $450M for 14th biotech fund, the same size as its 2022 raise (Endpoints)
• Novartis strikes radiopharma deal with Ratio worth up to $745M (Endpoints)
• Cybin says its psychedelic drug can sustain remission in depression patients (Endpoints)
• CVS adds four new board members in deal with Glenview as CEO pursues a turnaround (Reuters)
• With new patient resource to close conversation gaps in rheumatic disease, AbbVie makes 'Rheum for Dialogue' (Fierce Pharma)
• Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome (Fierce Pharma)
• Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ (Fierce Pharma)

• With rising cancer rates in younger adults, experts emphasize better tests (STAT)
• The PFA race is heating up. Here’s where the market stands after J&J’s approval (MedTech Dive)
• Boston Scientific’s Watchman could be new option for patients post ablation: study (MedTech Dive)
• FDA warns providers on Getinge devices tied to 17 serious injuries (MedTech Dive)
• Abbott Opens New Manufacturing Facility In Ireland For FreeStyle Libre 3 Production (MedTech Insight)
• UK Kicks Off Seven-Week Pre-Market Regulatory Consultation (MedTech Dive)

• First U.S. case of new mpox strain detected in California (STAT)
• Hospitals and insurers are optimistic Republicans will extend ACA subsidies (STAT)
• How RFK Jr. could strip legal protections from vaccine makers as HHS Secretary (STAT)
• Medical services provider CareMax files for Chapter 11 restructuring (Reuters)
• Even in “Unprecedented” Times, There is Precedent (FDA Law Blog)